Novo Nordisk Introduces $199 Introductory Deal for Wegovy and Ozempic Before Anticipated Price Reductions

Novo Nordisk Introduces $199 Introductory Deal for Wegovy and Ozempic Before Anticipated Price Reductions

Novo Nordisk is initiating new pricing options for self-pay patients, enhanced savings programs, and collaborations with telehealth and retail providers. This occurs as its obesity treatment portfolio gains traction under the FDA's National Priority Voucher program.

Wegovy (semaglutide) injection and Ozempic are being offered by Novo Nordisk at a price of $199 monthly for new self-pay patients until March 31, 2026, as part of a special promotion. This introductory deal applies to the first two months of treatment and is applicable to the 0.25 mg and 0.5 mg doses of either Wegovy or Ozempic.

Following the limited-time promotion, the monthly self-pay price will adjust to the standard rate of $349, which represents a $150 reduction.

Novo Nordisk is implementing these lower prices for consumers ahead of schedule, following a recent agreement to increase access to medicines for obesity and chronic diseases, while also lowering direct-to-patient costs in 2026.

Dave Moore, Novo Nordisk's EVP of US operations, stated, "As pioneers of the GLP-1 class, we are dedicated to ensuring that FDA-approved Wegovy and Ozempic are both affordable and readily available to those who require them." He further added that their new savings offers provide immediate financial relief for those without coverage or who choose to self-pay, as part of a broader strategy to improve access.

Patients can take advantage of these self-pay offers in various ways.

WeightWatchers recently indicated its intention to offer Novo Nordisk's oral version of Wegovy, pending FDA approval and US debut next year.

Currently, oral semaglutide for chronic obesity is undergoing FDA review and has not yet received approval. Accessibility and affordability plans will be communicated following approval, aligning with the mission to serve US obesity patients.

This development occurs as the FDA includes Wegovy in the Commissioner's National Priority Voucher (CNPV) program, which now encompasses 15 products addressing public health and national security priorities.

This CNPV pilot program allows eligible sponsors to secure a voucher, potentially reducing the FDA review time to one to two months, compared to the standard 10-12 months post-submission.

FDA Commissioner Marty Makary, MD, MPH, noted that national priority vouchers are awarded to products where the company commits to enhancing affordability, domesticating manufacturing for national security reasons, or addressing an unmet public health need.

Health tracking apps like Shotlee can help monitor treatment progress and adherence.

Novo Nordisk continues to provide savings programs for eligible patients with commercial insurance, potentially lowering monthly costs to as low as $0 for Wegovy and $25 for Ozempic.